JPH0330574B2 - - Google Patents
Info
- Publication number
- JPH0330574B2 JPH0330574B2 JP58000507A JP50783A JPH0330574B2 JP H0330574 B2 JPH0330574 B2 JP H0330574B2 JP 58000507 A JP58000507 A JP 58000507A JP 50783 A JP50783 A JP 50783A JP H0330574 B2 JPH0330574 B2 JP H0330574B2
- Authority
- JP
- Japan
- Prior art keywords
- clostridium
- bacteria
- bacterial
- poultry
- salmonella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001580 bacterial effect Effects 0.000 claims description 23
- 244000144977 poultry Species 0.000 claims description 14
- 241000193450 [Clostridium] symbiosum Species 0.000 claims description 10
- 239000007952 growth promoter Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 241000193462 [Clostridium] innocuum Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 description 14
- 235000013594 poultry meat Nutrition 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 241000607142 Salmonella Species 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 206010039438 Salmonella Infections Diseases 0.000 description 4
- 206010039447 salmonellosis Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000605909 Fusobacterium Species 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は家禽の発育促進剤に関する。
従来、家禽の発育促進剤として抗菌性物質が一
般に用いられているが、耐生菌および副作用の発
現などの問題があり満足のゆくものではなかつ
た。また最近抗菌性物質の代りに生菌製剤例えば
乳酸菌製剤が用いられているがその効果は不充分
である。
本発明者等は家禽の発育を促進する方法につい
て鋭意研究の結果、クロストリジウム・イノキユ
ウム(Clostridium innocuum)およびクロスト
リジウム・シンビオスム(Clostridium
symbiosum)の培養により得た菌体の投与が有
効であることを確認し本発明を完成させた。
すなわち本発明はクロストリジウム・イノキユ
ウムまたはクロストリジウム・シンビオスムを培
養して得られた菌体またはそれらの混合物を有効
成分とする家禽用発育促進剤である。
本発明に用いるクロストリジウム・イノキユウ
ムは「Bergey′s Manual of Determinative
Bacteriology」第8版(1974)に記載された性
状を有する。すなわち、菌の形態はグラム陽性有
芽胞桿菌で両端円形直線状で単在し、芽胞は卵円
形で端在性、菌端が膨隆するものがみられる。非
運動性、カタラーゼ陰性、インドール陰性であ
り、グルコースを発酵させて酪酸、酢酸およびイ
ソアミルアルコールを産生する。またクロストリ
ジウム・シンビオスムは最近金内ら
「International Journal of Systematic
Bacteriology」によつて有芽胞菌であることが
確認され、前記「Bergey′s Manual」第8版
(1974)に記載されているフソバクテリウム
(Fusobacterium)属からクロストリジウム属に
編入され、菌名もフソバクテリウム・シンビオス
ム(Fusobacterium symbiosum)から改名され
た菌株である。本菌はグラム陰性有芽胞桿菌であ
り、両端尖り、単在または二連鎖し、芽胞は球形
で偏在性、菌体の膨隆がみられるが芽胞形成しに
くい。非運動性、カタラーゼ陰性、インドール陰
性、PYGブロス(peptone yeast extract−
glucose broth)において酪酸および酢酸を産生
する。
前記2菌種は偏性嫌気性菌であるので、その培
養は嫌気条件下でおこなわねばならない。例えぱ
L−システイン塩酸塩とアスコルビン酸との混合
液を加熱滅菌直後の培地に適量添加し、培地中の
溶存酸素を除去する方法によれば静置培養でも容
易に嫌気培養ができる〔「臨床検査」第18巻第7
〜16頁(1974)参照〕。培養温度は約30〜42℃、
最適温度は約37℃前後でPHは中性付近で培養する
ことが望ましい。培養の終了後、培養液を約20℃
前後に冷却し、次に約2±2℃において連続遠心
分離して菌体を分離し且つ回収する。回収された
菌体はグルタミン酸ソーダ、リジンなどのアミノ
酸を含むリン酸バツフアーまたは水に分散せしめ
た後凍結乾燥する。なお投与する菌の形態として
は乾燥製剤、液状製剤など特に限定されず、また
飼料に混合して与えてもさしつかえない。
なお、本発明の発育促進剤が適用される家禽と
しては鶏、うずら、七面鳥、ほろほろ鳥、あひ
る、鵞鳥その他があげられる。
本発明の菌剤は経口投与により使用されるのが
好ましい。1日当り106個以上の投与量で顕著な
体重増加効果を示す。以下に具体的な例を挙げて
本発明のこのような効果について説明する。
生後0日令のブロイラー(ハバード種)を1回
の試験について1群20羽ずつ7群に分け、1区分
は対照(生理食塩水投与群)とし、残りの6群は
菌剤投与群とし、第1表に示す各菌種の凍結乾燥
菌体を生理食塩水で所定の濃度に希釈して用い
た。すなわち第1回試験では生理食塩水0.5ml当
り105個、第2回試験では同106個そして第3回試
験では同108個になるように調整し、生後0日令
から1週間にわたり毎日1回経口投与し、3週後
の体重増加および飼料要求率(体重1Kg増加する
のに要する飼料量(Kg))を求めた。第1表に示
すように、クロストリジウム属菌のうち特にクロ
ストリジウム・イノキユウムおよびクロストリジ
ウム・シンビオスムの2種に特異的に効果が認め
られた。
The present invention relates to a poultry growth promoter. Conventionally, antibacterial substances have been generally used as growth promoters for poultry, but these have not been satisfactory due to problems such as bacterial resistance and side effects. Recently, live bacteria preparations such as lactic acid bacteria preparations have been used instead of antibacterial substances, but their effects are insufficient. As a result of intensive research into methods for promoting the growth of poultry, the present inventors found that Clostridium innocuum and Clostridium symbiosum
The present invention was completed by confirming that administration of bacterial cells obtained by culturing M. symbiosum was effective. That is, the present invention is a poultry growth promoter containing as an active ingredient bacterial cells obtained by culturing Clostridium innoculum or Clostridium symbiosum, or a mixture thereof. The Clostridium inocium used in the present invention is “Bergey’s Manual of Determinative”.
Bacteriology, 8th edition (1974). In other words, the morphology of the bacteria is a Gram-positive spore-forming bacillus, which exists singly in a straight line shape with circular ends, and the spores are oval and endemic, and some have swollen ends. It is nonmotile, catalase negative, indole negative, and ferments glucose to produce butyrate, acetic acid, and isoamyl alcohol. In addition, Clostridium symbiosum was recently reported by Kanauchi et al., “International Journal of Systematic
It was confirmed to be a spore-forming bacterium by the ``Bergey's Manual,'' 8th edition (1974), and was transferred from the genus Fusobacterium to the genus Clostridium, and the bacterial name was also Fusobacterium. This strain was renamed from Fusobacterium symbiosum. This bacterium is a Gram-negative spore-forming bacillus, with pointed ends, singly or double-chained, and spores are spherical and ubiquitous, and although the bacterial body is swollen, it is difficult to form spores. Non-motile, catalase negative, indole negative, PYG broth (peptone yeast extract)
produces butyrate and acetate in glucose broth). Since the two bacterial species mentioned above are obligate anaerobic bacteria, their cultivation must be carried out under anaerobic conditions. For example, by adding an appropriate amount of a mixture of L-cysteine hydrochloride and ascorbic acid to a culture medium immediately after heat sterilization to remove dissolved oxygen in the culture medium, anaerobic culture can be easily achieved even in static culture. Inspection” Volume 18, No. 7
See pages 16 to 16 (1974)]. Culture temperature is approximately 30-42℃,
The optimal temperature is around 37°C and the pH is preferably around neutral. After culturing, keep the culture solution at about 20℃.
After cooling back and forth, the cells are separated and collected by continuous centrifugation at about 2±2°C. The recovered bacterial cells are dispersed in a phosphate buffer or water containing amino acids such as monosodium glutamate and lysine, and then freeze-dried. The form of the bacteria to be administered is not particularly limited, such as dry preparations or liquid preparations, and it may be mixed with feed and given. In addition, examples of poultry to which the growth promoter of the present invention is applied include chickens, quail, turkeys, guinea fowl, ducks, geese, and others. The fungal agent of the present invention is preferably used by oral administration. A significant weight gain effect is shown at doses of 10 6 or more per day. These effects of the present invention will be explained below with specific examples. For one test, 0-day-old broilers (Hubbard breed) were divided into 7 groups of 20 birds per group, 1 group was used as a control (physiological saline administration group), and the remaining 6 groups were treated as fungal agent administration groups. Freeze-dried bacterial cells of each bacterial species shown in Table 1 were diluted with physiological saline to a predetermined concentration and used. In other words, the number was adjusted to 10 5 pieces per 0.5 ml of saline in the first test, 10 6 pieces per 0.5 ml of saline in the second test, and 10 8 pieces per 0.5 ml of saline in the third test. It was orally administered once a day, and the weight gain and feed conversion rate (the amount of feed (Kg) required to increase body weight by 1Kg) after 3 weeks were determined. As shown in Table 1, specific effects were observed on two types of Clostridium bacteria, Clostridium inocium and Clostridium symbiosum.
【表】
更に予想外なことには本発明の家禽用発育促進
剤は家禽サルモネラ症に対して予防および治療効
果を有することが判つた。この点についての効果
を下記試験により示す。
生後0日令のブロイラー(ハバード種)を1回
の試験について1群10羽ずつ9群に区分けし、1
区分は対照(生理食塩水投与群)とした。残りの
8群は菌剤投与群とし、第1〜3表に示す各菌種
の凍結乾燥菌体を生理食塩水で所定の濃度に希釈
して使用した。
第1回試験(第2表)では生理食塩水0.5ml当
り106個、第2回試験(第3表)では同107個そし
て第3回試験(第4表)では同108個になるよう
に各凍結乾燥菌剤を調整し、孵化直後のひなに1
回経口投与した。翌日に108個のサルモネラ・テ
イフイミリウム(Salmonella typhimurium)を
含む生理食塩水0.5mlを経口投与し、サルモネラ
菌を感染させた。感染1週目にこれらのひなを屠
殺し、盲腸内容物中のサルモネラ菌数を調べたと
ころ、第2〜4表に示す結果が得られた。これら
の表からクロストリジウム属菌のうち、特にクロ
ストリジウム・イノキユウムおよびクロストリジ
ウム・シンビオスムの2種が特異的に有効である
ことが認められる。[Table] Furthermore, it was unexpectedly found that the poultry growth promoter of the present invention has preventive and therapeutic effects on poultry salmonellosis. The effect in this regard will be demonstrated by the following test. For one test, 0-day-old broilers (Hubbard breed) were divided into 9 groups of 10 birds each.
The group was classified as a control (physiological saline administration group). The remaining 8 groups were treated as bacterial agent administration groups, and lyophilized bacterial cells of each bacterial species shown in Tables 1 to 3 were diluted with physiological saline to a predetermined concentration and used. In the first test (Table 2), there were 106 pieces per 0.5ml of physiological saline, in the second test (Table 3) there were 107 pieces per 0.5ml, and in the third test (Table 4) there were 108 pieces per 0.5ml of saline. Adjust each freeze-dried fungicide so that
Administered orally. The next day, 0.5 ml of physiological saline containing 10 8 pieces of Salmonella typhimurium was orally administered to infect the mice with Salmonella bacteria. When these chicks were sacrificed one week after infection and the number of Salmonella bacteria in the cecal contents was examined, the results shown in Tables 2 to 4 were obtained. From these tables, it is recognized that among Clostridium genus bacteria, two species, Clostridium inocium and Clostridium symbiosum, are particularly effective.
【表】【table】
【表】【table】
【表】
また生後0日令のブロイラー(ハバード種)を
1群10羽ずつ5群に区分けし、第5表に示す各菌
種の凍結乾燥菌体を生理食塩水0.5ml当り105個に
なるように各凍結乾燥菌剤を調整し、孵化直後の
ひなに3日連続経口投与した。翌日108個のサル
モネラ・テイフイミリウムを含む生理食塩水0.5
mlを経口投与し、サルモネラ菌を感染させた。以
後前記と同様に処理して第5表に示す結果が得ら
れた。すなわち1回の投与菌量が105個と低い値
であつてもとくにクロストリジウム・イノキユウ
ムおよびクロストリジウム・シンビオスムの2種
に効果が認められる。[Table] In addition, 0-day-old broilers (Hubbard breed) were divided into 5 groups of 10 birds per group, and 10 5 freeze-dried cells of each bacterial species shown in Table 5 were prepared per 0.5 ml of physiological saline. Each freeze-dried fungal preparation was prepared and orally administered to chicks immediately after hatching for 3 consecutive days. The next day 10 saline containing 8 Salmonella teifimillium 0.5
ml was orally administered to infect with Salmonella. Thereafter, the same treatment as above was performed, and the results shown in Table 5 were obtained. In other words, even when the amount of bacteria administered at one time is as low as 10 5 bacteria, it is particularly effective against two species, Clostridium innoculum and Clostridium symbiosum.
【表】
さらにまた生後1週令のブロイラー(ハバード
種)297羽の糞便(盲腸便も含む)中のサルモネ
ラ菌を検査し、297羽中39羽にサルモネラ菌を認
めたので、それらサルモネラ陽性鶏を2区に分
け、1区分は対照(19羽)とし、残りの20羽を試
験区としてクロストリジウム・イノキユウムとク
ロストリジウム・シンビオスムとの混合凍結乾燥
菌剤を11日令から10日間にわたつて1羽当り108
個を経口投与した。3週令時の糞便中のサルモネ
ラ菌検出状況を調べた結果、第6表に示す結果が
得られた。この表から明らかなように、凍結乾燥
菌剤投与区においてサルモネラ菌検出率の低下が
認められる。[Table] Furthermore, we tested for Salmonella in the feces (including cecal stool) of 297 1-week-old broiler chickens (Hubbard breed) and found Salmonella in 39 of the 297 chickens. One group was used as a control (19 birds), and the remaining 20 birds were used as a test group. A freeze-dried fungicide mixture of Clostridium innoculum and Clostridium symbiosum was applied to each bird for 10 days from 11 days of age. 8
was administered orally. As a result of examining the detection status of Salmonella bacteria in feces at the age of 3 weeks, the results shown in Table 6 were obtained. As is clear from this table, a decrease in the Salmonella detection rate was observed in the lyophilized bacterial agent administration area.
【表】
前記第2〜6表から明らかなように、本発明の
菌剤は107個以上で1回かあるいは少なくとも105
個×3日の投与量で家禽サルモネラ症に対して顕
著な予防および治療効果を示す。
上記の説明から明らかなように、本発明の家禽
用発育促進剤は単なる発育促進に止まらず家禽サ
ルモネラ症の予防または治療作用を有するという
利点がある。従つて本明細書において「家禽用発
育促進剤」なる表現は(1)通常の家禽発育の促進お
よび(2)家禽サルモネラ症の予防または治療のいず
れか一方または両方を目的とした場合に有効なも
のである。
次に実施例を挙げて本発明菌剤の製法を説明す
る。
実施例 1
クロストリジウム・イノキユウム(本菌株は
1962年登録番号ATCC14501としてATCCに寄託
されている)1白金耳量をBTIブロス(ブレイン
ハートインフユージヨンブロス、デイフコ社製)
に植菌し、37℃で20時間培養した後、100倍量の
同一培地で37℃で20時間培養し、さらにもう一度
100倍量の同一培地で37℃で20時間培養する。培
養終了後、培養液を20℃に急速冷却し、次いで2
±2℃の条件で連続遠心分離機を用いて培養液よ
り菌体を分離した。
分離された菌体を菌体重量の10倍量の生理食塩
水に懸濁した後、再度遠沈することにより菌体を
洗浄した。この洗浄操作を再度繰返して10の培
養液より40mの湿菌体を得た。得られた菌体を菌
体量の10倍量の3%グルタミン酸ソーダおよび5
%可溶性殿粉加隣酸バツフアー液(隣酸2水素カ
リウム0.4%および隣酸水素ナトリウム1.0%含
有)に懸濁した後、凍結乾燥した。得られた凍結
乾燥菌体を粉砕して粉末にし、本発明の抗サルモ
ネラ菌剤を得た。この菌剤1g中にはクロストリ
ジウムイノキユウムの生菌を1011個含有してい
た。
実施例 2
クロストリジウム・イノキユウムの代りにクロ
ストリジウム・シンビオスム(本菌株は1976年登
録番号ATCC 14940としてATCCに寄託されてい
る)を用いる他は実施例1と同様にして本発明抗
サルモネラ菌剤を得た。この菌剤1g中にはクロ
ストリジウム・シンビオスムの生菌を1011個含有
していた。
実施例 3
実施例1および2の方法で得られたクロストリ
ジウム・イノキユウムおよびクロストリジウム・
シンビオスムの各凍結乾燥菌体粉末を1:1の割
合で混合して本発明の抗サルモネラ菌剤を得た。[Table] As is clear from Tables 2 to 6 above, the fungal agent of the present invention is used once for 10 7 or more, or at least 10 5
It exhibits remarkable preventive and therapeutic effects against poultry salmonellosis at a dose of 1 x 3 days. As is clear from the above description, the poultry growth promoter of the present invention has the advantage of not only merely promoting growth but also having preventive or therapeutic effects on poultry salmonellosis. Therefore, in this specification, the expression "poultry growth promoter" refers to an agent effective for (1) promoting normal poultry growth and (2) preventing or treating poultry salmonellosis, or both. It is something. Next, the method for producing the fungal agent of the present invention will be explained with reference to Examples. Example 1 Clostridium inocium (this strain is
1 platinum loop (deposited with ATCC in 1962 under registration number ATCC 14501) was added to BTI broth (Brain Heart Infusion Broth, manufactured by Difco).
After inoculating and culturing at 37℃ for 20 hours, culture in 100 times the volume of the same medium at 37℃ for 20 hours, and then once again.
Culture in 100 times the volume of the same medium at 37°C for 20 hours. After culturing, the culture solution was rapidly cooled to 20°C, and then
Bacterial cells were separated from the culture solution using a continuous centrifuge at ±2°C. The isolated bacterial cells were suspended in physiological saline in an amount 10 times the weight of the bacteria, and then centrifuged again to wash the bacterial cells. This washing operation was repeated again to obtain 40 m of wet bacterial cells from the 10 culture solutions. The obtained bacterial cells were mixed with 3% sodium glutamate in an amount 10 times the amount of bacterial cells and 5
% soluble starch in a phosphoric acid buffer solution (containing 0.4% potassium dihydrogen phosphate and 1.0% sodium hydrogen phosphate), and then freeze-dried. The obtained freeze-dried cells were ground into powder to obtain the anti-Salmonella agent of the present invention. One gram of this bacterial agent contained 10 to 11 viable Clostridium inocium bacteria. Example 2 An anti-Salmonella agent of the present invention was obtained in the same manner as in Example 1, except that Clostridium symbiosum (this strain has been deposited with the ATCC under registration number ATCC 14940 in 1976) was used instead of Clostridium inocium. One gram of this bacterial agent contained 10 to 11 live Clostridium symbiosum bacteria. Example 3 Clostridium inocium and Clostridium inocium obtained by the methods of Examples 1 and 2
The anti-Salmonella agent of the present invention was obtained by mixing the lyophilized cell powders of Symbiosum at a ratio of 1:1.
Claims (1)
(Clostridium innocuum)またはクロストリジウ
ム・シンビオスム(Clostridium symbiosum)
を培養して得られた菌体かもしくはそれら両方の
菌体の混合物を有効成分してなることを特徴とす
る、家禽用発育促進剤。1 Clostridium innocuum or Clostridium symbiosum
1. A growth promoter for poultry, characterized in that the active ingredient is bacterial cells obtained by culturing or a mixture of both bacterial cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58000507A JPS59128333A (en) | 1983-01-07 | 1983-01-07 | Growth promotor for domestic fowl |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58000507A JPS59128333A (en) | 1983-01-07 | 1983-01-07 | Growth promotor for domestic fowl |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59128333A JPS59128333A (en) | 1984-07-24 |
JPH0330574B2 true JPH0330574B2 (en) | 1991-04-30 |
Family
ID=11475677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58000507A Granted JPS59128333A (en) | 1983-01-07 | 1983-01-07 | Growth promotor for domestic fowl |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59128333A (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5044261B2 (en) * | 2007-04-09 | 2012-10-10 | 茂 中野 | Animal feed |
JP6617935B2 (en) | 2014-04-10 | 2019-12-11 | 国立研究開発法人理化学研究所 | Compositions and methods for the induction of Th17 cells |
CN107751096A (en) * | 2017-11-01 | 2018-03-06 | 何秀芬 | A kind of ZOUDIJI cultural method |
CN109526870A (en) * | 2018-12-29 | 2019-03-29 | 绿春县宏益禽业养殖有限公司 | A kind of cultural method of Lvchun County coptis chicken |
-
1983
- 1983-01-07 JP JP58000507A patent/JPS59128333A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS59128333A (en) | 1984-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2292706C (en) | Method for administering viable microorganism composition for poultry | |
US5604127A (en) | Probiotic for control of Salmonella in fowl produced by continuous culture of fecal/cecal material | |
DK2647694T3 (en) | BIOMASS OF DEATH LACTOBACILLUS FOR ANTIMICROBIAL USE AND PROCEDURE FOR PREPARING THEREOF | |
Weinack et al. | Competitive exclusion of intestinal colonization of Escherichia coli in chicks | |
US5451400A (en) | Nucosal competitive exclusion flora | |
JPH0759516B2 (en) | How to maintain the effectiveness of bacterial preparations | |
CA1266234A (en) | Method of binding microflora | |
EA012968B1 (en) | A preparation containing probiotic bacteria, methods for production thereof, products on the base of said preparation, their use and a growth substrate | |
WO1994011492A1 (en) | Method of favorably modifying poultry intestinal microflora | |
JPS6234727B2 (en) | ||
KR100357766B1 (en) | The methods for alleviating body weight loss and reducing harmful bacteria in the intestine of poultry during the feed withdrawal | |
EP0381700B1 (en) | The use of a fructooligosaccharid in the manufacture of a bacteriostatic composition for inhibiting the growth of Salmonella and a process for inhibiting the growth of Salmonella in a food animal | |
EP0564121A2 (en) | Formulation for the treatment of cancer comprising a bacterial extract | |
JPH0330574B2 (en) | ||
JPH0696537B2 (en) | Serum cholesterol elevation inhibitor | |
JP3220699B2 (en) | Poultry growth promoter | |
JPH085802B2 (en) | Poultry colibacillosis vaccine | |
Dubreuil et al. | Cell surface characteristics and virulence in mice of Pasteurella multocida | |
EP0512857A2 (en) | Composition comprising bacterial culture residue and decapsulated bacterial cells and its use | |
JPH0149246B2 (en) | ||
AU1296500A (en) | Bacteriostatic compositions for salmonellae | |
Emerson et al. | Biotin deficiency in the rat | |
JPH09227392A (en) | Antitumor agent and production thereof | |
JPS5946492B2 (en) | Lipid oxidation inhibitor | |
JPH0222734B2 (en) |